The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Testing the effect of providing an antidepressant and anxiety-type escitalopram for patients
with glioblastoma on patient's quality of life including the effect of treatment on mood and
cognition during treatment.Two subgroups will fill questionnaires :
- Questionnaire mini mental state exam (mmse) which is the maximum score of 30. A score of
below 24 indicates a flaw in the level of dementia
- Questionnaire depression / mood PHQ9P(Pa t i e n t H e a l t h Qu e s t i o n n a i r e
- 9)
- The M. D. Anderson Symptom Inventory (MDASI)
- Evaluation of the hospital situation awareness (clinical assessment and questionnaire)
- Cognitive assessment which will be carried out by the Department neuropsychological and
include:
- Executive function (Stroop)
- Abstract Reasoning (similarities)
- -Auditory and Spatial Attention (Digit span, Spatial span) visual memory and
remembering Literature
- Memory function - visual and auditory (ROCF, RAVLT)
- Language function: Naming and verbal fluency
- Mindstreems Neurotrax